Replies to post #5039 on Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

that might be the first increase in mavyret sales in a while

[dewophile]

“ABBV 2Q25 Mavyret sales=$375M, +23% QoQ, +2% YoY:”

+9.7% YoY in the US where they got the acute label approved towards the end of the quarter. Still hard to tell how much lift this approval will provide so early, but it might be more than just trivial